Bacillus Calmette-Guerin Initiates Intracellular Signaling in a Transitional Carcinoma Cell Line by Cross-Linking α5β1 Integrin-Reference-Cited by-同舟云学术

Bacillus Calmette-Guerin Initiates Intracellular Signaling in a Transitional Carcinoma Cell Line by Cross-Linking α5β1 Integrin

Published:2003-08 Issue:2 Volume:170 Page:605-610
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

CHEN FANGHONG¹,ZHANG GUANGJIAN¹,IWAMOTO YOSHIKI¹,SEE WILLIAM A.¹

Affiliation:

1. From the Department of Urology (FC, GZ, YI, WAS) and Human and Molecular Genetics Center (YI), Medical College of Wisconsin, Milwaukee, Wisconsin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference10 articles.

1. Intravesical therapy for superficial bladder cancer;Malkowicz;Semin Urol Oncol,2000

2. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response;Kavoussi;J Clin Invest,1990

3. Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin;Ratliff;Cancer Res,1987

4. Characterization of soluble fibronectin binding to Bacille Calmette-Guerin;Aslanzadeh;J Gen Microbiol,1989

5. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy;Esuvaranathan;J Urol,1995

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting integrin α5β1 in urological tumors: opportunities and challenges;Frontiers in Oncology;2023-07-06

2. Bacillus Calmette‑Guï¿½rin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival;Oncology Letters;2018-04-11

3. Recombinant h IFN-α2b-BCG inhibits tumor growth in a mouse model of bladder cancer;Oncology Reports;2015-05-18

4. Contributors to HMGB1 Release by Urothelial Carcinoma Cells in Response to Bacillus Calmette-Guérin;Journal of Urology;2013-10

5. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy;British Journal of Cancer;2013-09-24